Pfizer Inc. $PFE Shares Sold by New York State Teachers Retirement System

New York State Teachers Retirement System trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 1.9% in the fourth quarter, HoldingsChannel reports. The firm owned 4,663,998 shares of the biopharmaceutical company’s stock after selling 90,733 shares during the period. New York State Teachers Retirement System’s holdings in Pfizer were worth $116,134,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in PFE. Franklin Resources Inc. increased its stake in shares of Pfizer by 47.8% during the 3rd quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock valued at $638,787,000 after acquiring an additional 8,108,887 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Pfizer by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock valued at $13,479,520,000 after purchasing an additional 7,031,162 shares in the last quarter. Neuberger Berman Group LLC increased its position in shares of Pfizer by 203.8% in the third quarter. Neuberger Berman Group LLC now owns 9,012,811 shares of the biopharmaceutical company’s stock worth $229,346,000 after acquiring an additional 6,045,763 shares in the last quarter. Ameriprise Financial Inc. raised its stake in shares of Pfizer by 48.2% in the 3rd quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company’s stock valued at $468,174,000 after acquiring an additional 5,978,927 shares during the period. Finally, AQR Capital Management LLC lifted its holdings in shares of Pfizer by 120.9% during the 3rd quarter. AQR Capital Management LLC now owns 9,505,615 shares of the biopharmaceutical company’s stock valued at $230,986,000 after acquiring an additional 5,202,884 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Bank of America lowered their price target on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Thursday, April 9th. HSBC boosted their price objective on Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, March 17th. Morgan Stanley increased their target price on Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. BMO Capital Markets reiterated an “outperform” rating and set a $30.00 target price on shares of Pfizer in a report on Monday, March 9th. Finally, Royal Bank Of Canada reissued an “underperform” rating and set a $25.00 price target on shares of Pfizer in a research report on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $28.74.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Late‑stage trial win for ELREXFIO (elranatamab): Pfizer reported Phase 3 MagnetisMM‑5 results showing a statistically significant improvement in progression‑free survival for relapsed/refractory multiple myeloma, strengthening ELREXFIO’s commercial potential in a high‑value oncology indication. Reuters: Pfizer’s blood cancer drug meets main goal in late-stage trial
• Positive Sentiment: VYNDAMAX patent settlement extends US protection to 2031: Pfizer reached settlements with multiple generics makers that effectively push off generic entry for its tafamidis franchise, protecting an asset Reuters and industry reports estimate is worth several billion in annual sales. This preserves a key revenue stream. Yahoo Finance: Pfizer reaches settlement to extend VYNDAMAX patent protection
• Positive Sentiment: FDA accepted sBLA for PADCEV (priority review): Pfizer and Astellas announced the US FDA accepted a supplemental Biologics License Application for PADCEV, advancing a potential label expansion that could add to oncology revenues if approved. InsiderMonkey: Pfizer Among Best Medical Stocks Under $30 to Invest In?
• Neutral Sentiment: Q1 earnings preview and estimates: Analysts and services are focused on Pfizer’s May 5 Q1 report; consensus (Zacks) currently forecasts ~$13.8B in sales and $0.74 EPS, so results that deviate from these metrics could move the stock. Zacks: Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q1 Earnings
• Neutral Sentiment: Market positioning and product markets: Reports note Pfizer’s participation in growing OTC markets (e.g., dry‑eye drops) and ongoing analyst coverage that highlights mixed sentiment — positive for pipeline progress but cautious on near‑term growth. Yahoo Finance: $4+ Billion OTC Dry Eye Drops Market Analysis
• Negative Sentiment: Competitive pressure from Alnylam’s Amvuttra: Alnylam’s strong Q1 beat and a near‑200% move for its heart‑disease drug underscore competitive dynamics in certain cardiometabolic portfolios — a reminder that product launches by peers can affect market share and sentiment in overlapping indications. Yahoo Finance: Alnylam surges after its Pfizer‑rivaling blockbuster jumps nearly 200%
• Negative Sentiment: Minor analyst estimate tweaks: Erste Group made a very small FY2027 EPS trim, and some analysts express mixed views — not a large revision but a headwind if further downgrades occur ahead of earnings. (No link)

Pfizer Stock Up 1.8%

Shares of NYSE:PFE opened at $26.75 on Friday. The firm has a market cap of $152.08 billion, a PE ratio of 19.67 and a beta of 0.43. The company has a fifty day simple moving average of $27.17 and a 200 day simple moving average of $26.09. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 12-month low of $21.97 and a 12-month high of $28.75.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.09. The company had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same period last year, the business earned $0.63 EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.4%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s payout ratio is currently 126.47%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.